Trial Number
179-21
Condition
Uterine Cancer
Participant Age Range
18 years and older
Participant Gender
Female
Enrolling Participants
No
Overview
“A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer”
This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study designed to evaluate maintenance treatment with selinexor compared with placebo in patients with endometrial cancer in partial or complete remission according to RECIST v1.1 who have completed a single line of at least 12 weeks of taxane-platinum combination therapy.